C-squared Pharma
C-squared Pharma, also known as C2 Pharma, is a prominent player in the pharmaceutical industry, headquartered in Germany (DE). Founded in 2015, the company has rapidly established itself as a leader in the development and distribution of high-quality pharmaceutical products, particularly in the areas of specialty pharmaceuticals and generics. With a strong operational presence across Europe, C-squared Pharma focuses on delivering innovative solutions that address unmet medical needs. Their core offerings include a diverse range of injectable and oral medications, distinguished by their commitment to quality and regulatory compliance. Recognised for its robust market position, C-squared Pharma has achieved significant milestones, including strategic partnerships and a growing portfolio of licensed products. The company continues to enhance its reputation as a trusted provider in the pharmaceutical landscape, dedicated to improving patient outcomes.
DitchCarbon Score
How does C-squared Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
C-squared Pharma's score of 0 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
C-squared Pharma's reported carbon emissions
C-squared Pharma, headquartered in Germany (DE), currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. In the absence of concrete emissions data, it is important to note that C-squared Pharma has not outlined any specific reduction targets or initiatives related to carbon emissions. Additionally, there are no commitments to the Science Based Targets initiative (SBTi) or any climate pledges mentioned. As the pharmaceutical industry increasingly focuses on sustainability and climate action, C-squared Pharma's lack of publicly available emissions data and reduction commitments may reflect a broader industry context where transparency and accountability are becoming essential. The company may need to consider establishing measurable targets and reporting frameworks to align with global climate goals and enhance its environmental stewardship.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
C-squared Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
